FDA expands use of telescope implant for AMD in patients ages 65 and up
The FDA has approved a 180-day supplement application for VisionCare Ophthalmic Technologies' PMA 180-day supplement application of the implantable miniature telescope for use in patients with end-stage age-related macular degeneration who are 65 years and older. The telescope implant is integral to the CentraSight treatment program, VisionCare said, which is proven to restore vision and improve quality of life in older adults with end stage AMD. According to the company, it is the only FDA-approved surgical device for end-stage AMD and is Medicare eligible.
Watching the Watchman and watching FDA
There is certainly no shortage of stories (or controversy) in the world of med tech, and here are a couple of stories that kept a lot of people glued to their computer screens (more or less) recently.
Protectionist policy being pursued: China to promote domestic devices among its top hospital facilities
Chinese authorities reported on Aug. 16 that they would establish a methodology to promote Chinese medical devices among top tier hospitals nationwide. The government made the announcement at a joint meeting of the National Health and Family Planning Commission (NHFPC) and the Ministry of Industry and Information Technology (MIIT).